Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | TLR8 | Q9NR97 | 5/20 | 0.43 |
| ▸ | TLR7 | Q9NYK1 | 5/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ASPH | Q12797 | 1/20 | 0.38 |
| ▸ | RIOX2 | Q8IUF8 | 1/20 | 0.38 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2571205 | 0.86 | HDAC6 (0.71) | HDAC6HDAC1HDAC8TLR8TLR7 | |
| SCHEMBL12287570 | 0.84 | HDAC6 (0.55) | HDAC6HDAC1HDAC8TLR8TLR7 | |
| SCHEMBL2566149 | 0.81 | HDAC6 (0.64) | HDAC6HDAC1HDAC8TLR8TLR7 | |
| SCHEMBL2554489 | 0.79 | MAPT (0.49) | HDAC6HDAC1HDAC8MEN1KMT2A | |
| SCHEMBL2572116 | 0.77 | HDAC6 (0.59) | HDAC6HDAC1HDAC8TLR8TLR7 | |
| SCHEMBL1424836 | 0.76 | HDAC6 (1.00) | HDAC6HDAC1HDAC8SIGMAR1MEN1 | |
| SCHEMBL29351335 | 0.76 | HDAC6 (1.00) | HDAC6HDAC1HDAC8SIGMAR1MEN1 | |
| SCHEMBL14658365 | 0.72 | HDAC6 (0.42) | HDAC6HDAC1HDAC8KDM4E | |
| SCHEMBL2564214 | 0.72 | HDAC6 (0.52) | HDAC6HDAC1HDAC8 | |
| SCHEMBL11598417 | 0.72 | MAPT (0.64) | HDAC6HDAC1HDAC8SIGMAR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2555623-A1 | FLAVIN DERIVATIVES | BioRelix, Inc. (US) | 2013-02-13 | — | — | EP | disclosed |
| US-20130029980-A1 | FLAVIN DERIVATIVES | COISH PHILIP D G (US) | 2013-01-31 | — | — | US | disclosed |
| US-20130029980-A1 | FLAVIN DERIVATIVES | COISH PHILIP D G (US) | 2013-01-31 | — | — | US | disclosed |
| US-20130029980-A1 | FLAVIN DERIVATIVES | COISH PHILIP D G (US) | 2013-01-31 | — | — | US | disclosed |
| WO-2011126567-A1 | FLAVIN DERIVATIVES | BIORELIX, INC. (US) | 2011-10-13 | — | — | WO | disclosed |
| WO-2011126567-A1 | FLAVIN DERIVATIVES | BIORELIX, INC. (US) | 2011-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029980-A1 | FLAVIN DERIVATIVES | BLVRB, FLAD1, FDPS | HDAC6 1870/4885HDAC1 2358/4885HDAC8 2411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.